CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 524296-524597 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T71580","span":{"begin":0,"end":301},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A phase 2 clinical trial (CAMMS-223) has shown the lymphocytedepleting humanised monoclonal antibody alemtuzumab to be highly effective in the treatment of early relapsing-remitting multiple sclerosis; reducing the risk of relapse and accumulation of disability by N70% compared to interferon beta-1a."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T179","span":{"begin":0,"end":301},"obj":"Sentence"}],"text":"A phase 2 clinical trial (CAMMS-223) has shown the lymphocytedepleting humanised monoclonal antibody alemtuzumab to be highly effective in the treatment of early relapsing-remitting multiple sclerosis; reducing the risk of relapse and accumulation of disability by N70% compared to interferon beta-1a."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3327","span":{"begin":162,"end":200},"obj":"Disease"},{"id":"T3328","span":{"begin":182,"end":200},"obj":"Disease"},{"id":"T85760","span":{"begin":162,"end":200},"obj":"Disease"},{"id":"T96183","span":{"begin":182,"end":200},"obj":"Disease"}],"attributes":[{"id":"A3327","pred":"mondo_id","subj":"T3327","obj":"http://purl.obolibrary.org/obo/MONDO_0005314"},{"id":"A3328","pred":"mondo_id","subj":"T3328","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A44572","pred":"mondo_id","subj":"T85760","obj":"http://purl.obolibrary.org/obo/MONDO_0005314"},{"id":"A97684","pred":"mondo_id","subj":"T96183","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"A phase 2 clinical trial (CAMMS-223) has shown the lymphocytedepleting humanised monoclonal antibody alemtuzumab to be highly effective in the treatment of early relapsing-remitting multiple sclerosis; reducing the risk of relapse and accumulation of disability by N70% compared to interferon beta-1a."}